**Table 1 - Demographic, clinical characteristics and symptoms of the whole Italian population, and of COVID-19-suspect patients compared to the non-suspect COVID-19 patients.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Whole Italian sample****(n. 929)** | **COVID-19 suspect group****(n. 14)** | **Non-suspect COVID-19 group****(n. 915)** | **p-value** |
| **Sex** |  |  |  | 0,164 |
| Female | 631 (67,92%) | 12 (86,67%) | 619 (67,79%) |  |
| Male | 298 (32,08%) | 2 (13,33%) | 296 (32,31%) |  |
| **Age (years)** |  |  |  | 0,467 |
| < 18  | - | - | - |  |
| 19-50  | 662 (71,26%) | 8 (60%) | 654 (71,52%) |  |
| 51-70  | 258 (27,77%) | 6 (40%) | 252 (27,49%) |  |
| > 70 | 9 (0,97%) | 0 (0%) | 9 (0,99%) |  |
| **Region of Italy n. 904** |  |  |  | 0,725 |
| South | 507 (56,02%) | 7 (50%) | 500 (56,18%) |  |
| Centre | 94 (10,39%) | 2 (14,29%) | 92 (10,34%) |  |
| North | 303 (33,59%) | 5 (35,71%) | 298 (33,48%) |  |
| **Comorbidities** |  |  |  |  |
| Hypertension | 125 (13,46%) | 0 (0%) | 125 (13,69%) | 0,112 |
| Diabetes/heart disease | 51 (5,49%) | 1 (6,67%) | 50 (5,48%) | 0,575 |
| Kidney disease | 4 (0,43%) | 0 (0%) | 4 0,44 | 0,973 |
| Cancer on chemotherapy | 7 (0,75%) | 0 (0%) | 7 (0,77%) | 0,892 |
| **Ongoing DMT (as dummy variable)** **n. 785**  |  |  |  | **0,047** |
| Moderate/High risk of infection DMTs | 175 (22,36%) | 6/13 (46,15%) | 169/772 (21,89%) |  |
| Very low/low risk of infection DMTs | 610 (77,64%) | 7/13 (53,85%) | 603/772 (78,11%) |  |
| **Previous DMT (as dummy variable)** **n. 636**  |  |  |  | 0,483 |
| Moderate/High risk of infection DMTs | 50 (7,85%) | 1/8 (12,5%) | 49/628 (7,80%) |  |
| Very low/low risk of infection DMTs | 586 (92,15%) | 7/8 (87,50%) | 579/628 (92,20%) |  |
| **Ongoing DMT category** |  |  |  | 0,082 |
| No therapy | 142 (15,39%) | 1 (6,67%) | 141 (15,55%) |  |
| Injection therapies | 154 (16,47%) | 0 (0%) | 154 (16,76%) |  |
| Oral therapy or immune cell trafficking-inhibitor | 457 (49,19%) | 7 (53,33%) | 450 (49,18%) |  |
| Low risk depletive therapies | 144 (15,50%) | 5 (33,33%) | 139 (15,12%) |  |
| High risk depletive therapies | 32 (3,44%) | 1 (6,67%) | 31 (3,4%) |  |
| **Lymphocyte count** **n. 234** |  |  |  | 0,227 |
| > 1400/mm3 | 82 (35,04%) | 6/14 (40%) | 76/220 (34,93%) |  |
| 701- 1400/mm3 | 72 (30,77%) | 0/14 (0%) | 72/220 (31,44%) |  |
| 501-700/mm3 | 20 (8,55%) | 0/14 (0%) | 20/220 (8,73%) |  |
| 200-500/mm3 | 60 (25,64%) | 8/14 (60%) | 52/220 (24,89%) |  |
| **Contact** |  |  |  | <0,001 |
| No contact | 842 (90,64%) | 4 (26,67%) | 840 (91,79%) |  |
| Contact with people from high risk or lock-down areas | 46 (4,95%) | 2 (13,33%) | 44 (4,82%) |  |
| Contact with a suspect case of COVID-19 infection | 22 (2,37%) | 6 (46,67%) | 14 (1,53%) |  |
| Contact with a confirmed case of COVID-19  | 19 (2,05%) | 2 (13,33%) | 17 (1,86%) |  |
| **Symptoms** |  |  |  |  |
| Sore throat, Nasal congestion, Runny nose, Diarrhea | 45 (4,85%) | 11 (80%) | 34 (3,62%) | <0,001 |
| Dry cough | 17 (1,83%) | 3 (20%) | 14 (1,54%) | <0,001 |
| Fever | 4 (0,43%) | 2 (13,33%) | 2 (0,22%) | <0,001 |
| Breathing difficulties, shortness of breath | 17 (1,83%) | 4 (33,33%) | 13 (1,32%) | <0,001 |
| Loss or reduced sense of smell and/or taste | 9 (0,97%) | 1 (6,67%) | 8 (0,88%) | <0,001 |

**Table 2 - Demographic, clinical characteristics and symptoms of the whole Iranian sample, and of COVID-19-suspect patients compared to the non-suspect COVID-19 patients.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Whole Iranian sample****(n 1346)** | **COVID-19 suspect group****(n 66)** | **Non.suspect COVID-19 group****(n 1280)** | **p-value** |
| **Sex** |  |  |  | 0,144 |
| Female | 1062 (78,9%) | 56 (84.85%) | 1006 (78.59%) |  |
| Male | 284 (21,1%) | 10 (15.15%) | 274 (21,41%) |  |
| **Age (years)** |  |  |  | 0,081 |
| < 18  | 10 (0,74%) | 0 (0%) | 10 (0,78%) |  |
| 19-50  | 1204 (89,45%) | 61 (92,42%) | 1143 (89,30%) |  |
| 51-70  | 131 (9,73%) | 5 (7,58%) | 126 (9,84%) |  |
| > 70 | 1 (0,07%) | 9 (0%) | 1 (0,08%) |  |
| **Comorbidities** |  |  |  |  |
| Hypertension | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Kidney disease | 7 (0,52%) | 0 (0%) | 7 (0,55%) | 0,703 |
| Diabetes/Heart disease | 59 (4,38%) | 10 (15,15%) | 49 (3,83%) | **<0,001** |
| Cancer on chemotherapy | 6 (0,45%) | 1 (1,52%) | 5 (0,39%) | 0,261 |
| **Ongoing DMT (as dummy variable)** **n. 914**  |  |  |  | 0,195 |
| Moderate/High risk of infection DMTs | 36 (3,94%) | 3/39 (7,69%) | 33/878 (3,77%) |  |
| Very low/low risk of infection DMTs | 878 (96,06%) | 36/39 (92,31) | 842/878 (96,23%) |  |
| **Previous DMT (as dummy variable)** **n. 759**  |  |  |  | 0,2 |
| Moderate/High risk of infection DMTs | 5 (0,66%) | 1/33 (3,03%) | 4/754 (0,55%) |  |
| Very low/low risk of infection DMTs | 754 (99,34%) | 32/33 (96,97%) | 722/754 (99,45%) |  |
| **DMT category** |  |  |  | 0,201 |
| No therapy | 432 (32,1%) | 27 (40,91%) | 405 (31,62%) |  |
| Injection therapies | 596 (44,28%) | 23 (34,85%) | 573 (44,77%) |  |
| Oral therapy or immune cell trafficking-inhibitor | 282 (20,95%) | 13 (19,70%) | 269 (21,02%) |  |
| Low risk depletive therapies | 36 (2,67%) | 3 (4,55%) | 33 (2,58%) |  |
| High risk depletive therapies | 0 (0%) | 0 (0%) | 0 (0%) |  |
| **Lymphocyte count**  |  |  |  | - |
| > 1400/mm3 | **NA** | **NA** | **NA** |  |
| 701- 1400/mm3 | **NA** | **NA** | **NA** |  |
| 501-700/mm3 | **NA** | **NA** | **NA** |  |
| 200-500/mm3 | **NA** | **NA** | **NA** |  |
| **Contact** |  |  |  | <0,001 |
| No contact | 1193 (88,63%) | 41 (62,12%) | 1152 (90%) |  |
| Contact with people from high risk or lock-down areas | 101 (7,5%) | 6 (9,09%) | 95 (7,42%) |  |
| Contact with suspect case of COVID-19 infection | 33 (2,45%) | 11 (16,67%) | 22 (1,72%) |  |
| Contact with confirmed case of COVID-19  | 19 (1,41%) | 8 (12,12%) | 11 (0,86%) |  |
| **Symptoms** |  |  |  |  |
| Sore throat, Nasal congestion, Runny nose, Diarrhea | 91 (6,76%) | 41 (62,12%) | 50 (3,91%) | <0,001 |
| Dry cough | 51 (3,79%) | 20 (46,97%) | 31 (1,56%) | <0,001 |
| Fever | 23 (1,71%) | 15 (22,73%) | 8 (0,62%) | <0,001 |
| Breathing difficulties, shortness of breath | 63 (4,68%) | 31 (46,97%) | 32 (2,5%) | <0,001 |
| Loss or reduced sense of smell and/or taste | 48 (3,57%) | 25 (37,88%) | 23 (1,80%) | <0,001 |

**Table 3 – Results of logistic regression model in the Iranian population.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Odds Ratio** | **95% CI** | **P value** |
| **Sex** | 0,592 | 0,295 – 1,188 | 0.141 |
| **Age** | 0,558 | 0,235 – 1,326 | 0.187 |
| **DMT category (compared to no DMT)** |  |  |  |
| *Injection therapies* | 0,576 | 0,322 – 1,029 | 0,062 |
| *Oral therapy or immune cell trafficking-inhibitor* | 0,604 | 0,300 – 1,216 | 0,159 |
| *Low risk depletive therapies* | 1,384 | 0,382 – 5,010 | 0,620 |
| *High risk depletive therapies\** | NA | NA | NA |
| **Hypertension\*** | NA | NA | NA |
| **Renal\*** | NA | NA | NA |
| **Diabetes/Heart Disease** | 5,374 | 2,470 – 11,695 | **< 0,001** |
| **Cancer on chemotherapy** | 2,410 | 0,227 – 25,508 | 0,465 |

\* No patients in the COVID-19 suspect group reported hypertension, renal impairment or to receive high risk depletive therapy.

Legend to table 1, 2 and 3

DMT: disease modifying therapy